Sangbin Lim

Publication Activity (10 Years)

Years Active: 2020-2020
Publications (10 Years): 2

Top Topics

Peritoneal Dialysis

Tyrosine Kinase

Machine Learning

Endoplasmic Reticulum Stress

Top Venues

Molecular cancer therapeutics

Cancer discovery

Yonsei University

Kyung Hee University College of Medicine (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Yonsei University May 02 2018

South Korea

Research assistant professor :: Yonsei Cancer Research Institute

University of South Alabama Mitchell Cancer Institute Feb 15 2014 - Jan 30 2018

United States

Post-Doctoral Fellow :: Oncologic Science

Education History

Kyung Hee University College of Medicine Mar 01 2009 - Aug 20 2013

South Korea

PHD :: Biochemistry and Molecular Biology

Publications

Jiyeon Yun, Soo-Hwan Lee, Seok-Young Kim, Seo-Yoon Jeong, Kyoung-Ho Pyo, Chae-Won Park, Seong Gu Heo, Mi Ran Yun, Sangbin Lim, Min Hee Hong, Meena Thayu, Joshua C Curtin, Roland E Knoblauch, Matthew V Lorenzi, Amy Roshak, Byoung Chul Cho
Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC. Cancer discovery 10 (8) (2020)
Nicolas Floc'h, Sangbin Lim, Sue Bickerton, Afshan Ahmed, Jonathan Orme, Jelena Urosevic, Matthew J Martin, Darren A E Cross, Byoung Chul Cho, Paul D Smith
Osimertinib, an Irreversible Next-Generation EGFR Tyrosine Kinase Inhibitor, Exerts Antitumor Activity in Various Preclinical NSCLC Models Harboring the Uncommon EGFR Mutations G719X or L861Q or S768I. Molecular cancer therapeutics 19 (11) (2020)